Author

M. D. Zimmerman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:genetic perturbation / CRISPR· 1 Organism:non-human primate· 1

Frequent Co-Authors

V. A. Dartois· 3 shared C. M. Sassetti· 2 shared D. Schnappinger· 2 shared N. Ruecker· 2 shared V. Dartois· 2 shared A. A. Bauman· 1 shared A. G. White· 1 shared A. Garcia· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

V. A. Dartois

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses

N. D. Walter, J. P. Ernest, C. Dide-Agossou, A. A. Bauman, M. E. Ramey, K. Rossmassler, L. M. Massoudi, S. Pauly, R. Al Mubarak, M. I. Voskuil, F. Kaya, J. P. Sarathy, M. D. Zimmerman, V. Dartois, B. K. Podell, , G. T. Robertson

The paper shows that Mycobacterium tuberculosis in different lung microenvironments have distinct phenotypes and treatment responses in a mouse model.

bioRxiv · Feb 3, 2023 · PreprintMicrobiology

Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and/or OPC-167832 in murine tuberculosis models

E. Nuermberger, R. Tasneen, A. Garcia, P. J. Converse, M. D. Zimmerman, V. A. Dartois, E. V. Kurbatova, A. Vernon, W. Carr, J. E. Stout, K. E. Dooley

This paper tests novel tuberculosis treatment regimens in mice, finding that BZM-based regimens show improved sterilizing activity compared to standard care.

bioRxiv · Dec 21, 2021Microbiology

A chemical-genetic map of the pathways controlling drug potency in Mycobacterium tuberculosis

S. Li, N. C. Poulton, J. S. Chang, Z. A. Azadian, M. A. Dejusus, N. Ruecker, M. D. Zimmerman, K. Eckartt, B. Bosch, C. A. Engelhart, D. Sullivan, M. Gengenbacher, V. A. Dartois, D. Schnappinger, J. M. Rock

This study uses a CRISPR interference platform to map drug resistance pathways in Mtb, identifying new intrinsic and acquired resistance mechanisms and potential drug targets.

bioRxiv · Nov 27, 2021 · PreprintMicrobiology

Chemical-genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy

E.-I. Koh, P. O. Oluoch, N. Ruecker, M. K. Proulx, V. Soni, K. C. Murphy, K. G. Papavinasasundaram, C. J. Reames, C. Trujillo, A. Zaveri, M. D. Zimmerman, R. Aslebagh, R. E. Baker, S. A. Shaffer, K. M. Guinn, , C. M. Sassetti

This study maps chemical-genetic interactions in Mycobacterium tuberculosis to identify how carbon metabolism and cell wall structure affect drug efficacy, revealing environment-dependent and -independent interactions.

bioRxiv · Apr 8, 2021Microbiology

Evaluation of IL-1 blockade as an adjunct to linezolid therapy for tuberculosis in mice and macaques

C. G. M. Winchell, B. B. Mishra, J. Y. Phuah, M. Saqib, S. J. Nelson, P. Maiello, C. M. Causgrove, C. L. Ameel, B. Stein, H. J. Borish, A. G. White, E. C. Klein, M. D. Zimmerman, V. Dartois, P. L. Lin, , J. L. Flynn

This study evaluates IL-1 blockade as an adjunct to linezolid therapy for tuberculosis in mice and macaques, finding reduced inflammation and preserved host response without impairing treatment efficacy.

Frontiers in Immunology · May 12, 2020Peer-reviewedMicrobiology